Veteran health innovation and policy leader to drive biotechnology innovation, startup growth and commercialization of indigenous technologies
Acquisition of Mumbai-based pharmaceutical, nutraceutical and cosmeceutical company expected to be completed by July 2026
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
The new facility will produce precision extruded medical tubing used in minimally invasive medical devices
The expanded approval covers children and teens with chronic conditions that increase vulnerability to pneumococcal infections
The collaboration is focused on overcoming a major limitation in existing cancer drugs
Seasoned pharmaceutical R&D leader takes on an expanded leadership role to drive innovation and strengthen Hetero’s advanced formulation development capabilities
Upon completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences and will be delisted from the Nasdaq
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Subscribe To Our Newsletter & Stay Updated
